Anti-interleukin-17 treatment of psoriasis

Jinna, Sphoorthi; Strober, Bruce

doi:10.3109/09546634.2015.1115816

Cited by 14 publications

(9 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For psoriasis, it is now well established that interleukin IL-17 is involved in the formation of the skin lesions, a notion recently confirmed in humans by the success of monoclonal antibodies against IL-17A or the receptor IL-17RA in controlling and reversing the skin disease [89]. These treatments are now on the market or in phase III trials with great safety profiles and they are highly efficacious [90]. Although successful, employing monoclonal antibodies against chronic diseases can be a costly endeavor, and vaccination stands as a more cost-effective alternative.…”

Section: Nps For Chronic Non-communicable Diseasesmentioning

confidence: 99%

Harnessing Nanoparticles for Immunomodulation and Vaccines

2017

View full text Add to dashboard Cite

The first successful use of nanoparticles (NPs) for vaccination was reported almost 40 years ago with a virus-like particle-based vaccine against Hepatitis B. Since then, the term NP has been expanded to accommodate a large number of novel nano-sized particles engineered from a range of materials. The great interest in NPs is likely not only a result of the two successful vaccines against hepatitis B and Human Papilloma Virus (HPV) that use this technology, but also due to the versatility of those small-sized particles, as indicated by the wide range of applications reported so far, ranging from medicinal and cosmetics to purely technical applications. In this review, we will focus on the use of NPs, especially virus-like particles (VLPs), in the field of vaccines and will discuss their employment as vaccines, antigen display platforms, adjuvants and drug delivery systems.

show abstract

Section: Nps For Chronic Non-communicable Diseasesmentioning

confidence: 99%

Harnessing Nanoparticles for Immunomodulation and Vaccines

2017

View full text Add to dashboard Cite

show abstract

“…The IL‐17 cytokine pathway plays an important role in the pathogenesis of psoriasis, and is a highly effective therapeutic target offering an alternate mechanism of action to both TNF‐α and IL‐12/IL‐23 inhibitors . Brodalumab is unique among the biological drugs targeting IL‐17, as it is a fully human monoclonal antibody targeting IL‐17 receptor A.…”

mentioning

confidence: 99%

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The secretion of IL-12 and IL-23 by the myeloid dendritic cells causes naïve T cells to differentiate into helper type (Th)17 and type 1 Th (Th1) cells. The maintenance and production of Th1 cells is primarily maintained by IL-12, whereas IL-23, composed of IL-23p19 and IL-23p40 protein subunits, is the predominant driver involved in Th17 cell differentiation 7,13–17. The effector T cells then migrate back into the skin where they release cytokines and chemokines driving the proliferation of keratinocytes.…”

Section: Role Of Il-17 In the Pathogenesis Of Psoriasismentioning

confidence: 99%

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab

Hanley¹,

Yiu²

2017

TCRM

View full text Add to dashboard Cite

Developments in the understanding of the immunopathogenesis of psoriasis have identified interleukin (IL)-17 as the key proinflammatory cytokine in the pathogenesis of plaque psoriasis, with the consequent development of drugs that target this cytokine or associated receptors. Ixekizumab is a subcutaneously administered humanized monoclonal antibody, which acts to neutralize IL-17A. This article reviews the role of IL-17 in the pathogenesis of psoriasis, the biological and pharmacokinetics of ixekizumab and the safety profile and the clinical efficacy of ixekizumab in Phase III clinical trials. Phase III clinical trials of ixekizumab have so far demonstrated excellent early clinical efficacy, with a comparable safety profile to the existing biologic therapies for psoriasis. To further assess its position in the treatment algorithm for psoriasis, a further head to head RCT with secukinumab could be established, alongside comparative effectiveness studies from observational research. In addition, trials are needed to assess its role in those with tumor necrosis factor inhibitors/ustekinumab resistant disease. However, it is clear that the IL-17 antagonists have changed the benchmark for clinical efficacy, and it is likely that ixekizumab along with the other IL-17 antagonists are set to achieve a new standard of care in the treatment of moderate to severe plaque psoriasis.

show abstract

Anti-interleukin-17 treatment of psoriasis

Cited by 14 publications

References 28 publications

Harnessing Nanoparticles for Immunomodulation and Vaccines

Harnessing Nanoparticles for Immunomodulation and Vaccines

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab

Contact Info

Product

Resources

About